Free Trial
LON:ONC

Oncimmune (ONC) Share Price, News & Analysis

Oncimmune logo

About Oncimmune Stock (LON:ONC)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
1.14
8.01
52-Week Range
N/A
Volume
N/A
Average Volume
589,365 shs
Market Capitalization
£1.29 million
P/E Ratio
0.13
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.

Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncimmune and its competitors with MarketBeat's FREE daily newsletter.

ONC Stock News Headlines

What President Trump’s Executive Order 14154 means for your money
Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.
Oncimmune Share Chat (ONC)
See More Headlines

ONC Stock Analysis - Frequently Asked Questions

Oncimmune Holdings plc (LON:ONC) released its quarterly earnings data on Monday, February, 10th. The company reported ($4.72) earnings per share for the quarter. Oncimmune had a net margin of 581.63% and a negative trailing twelve-month return on equity of 2,277.74%.

Shares of ONC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncimmune investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), Intel (INTC) and IQE (IQE).

Company Calendar

Last Earnings
2/10/2025
Today
4/24/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:ONC
CIK
N/A
Fax
N/A
Employees
52
Year Founded
N/A

Profitability

Trailing P/E Ratio
0.13
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£10.79 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£1.86 million
Price / Cash Flow
11.96
Book Value
GBX (1.72) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
£1.29 million
Optionable
Not Optionable
Beta
1.19
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (LON:ONC) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners